Compare NetEase Inc (NTES) vs Viatris Inc (VTRS) Price & Performance

NetEase (NTES) trades at $119.45, up 0.13% on the day, with a bearish technical signal from moving averages and mixed earnings performance including a Q2 2026 EPS miss. The company maintains strong profitability with a 27.88% net income margin and robust cash flow, though net cash flow turned negative in 2025. Recent news highlights dividend growth and international expansion efforts amid competitive pressures.

The stock presents a valuation opportunity with a P/E of 15.93 below sector averages, supported by an 81.82% analyst buy rating. Key risks include earnings volatility and heavy investing outflows, but solid fundamentals and global growth initiatives offer long-term upside potential for patient investors.

Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.

The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.